Neuroscientific Biopharmaceuticals Ltd. has released a press release.
Leading CRO Appointed for Phase 2 Crohn's Trial
Earlier from Neuroscientific Biopharmaceuticals
- 2026 Annual Report & Appendix 4E
- Remarkable Results from Patients treated with StemSmart
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report